GO:0070700 BMP receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070700 (BMP receptor binding) is a molecular function defined as binding to a BMP receptor, with the synonym bone morphogenetic protein receptor binding.
• BMP receptor binding is the first committed step in BMP/TGF-beta signaling and determines which of the type I receptors (ALK2/ACVR1, ALK3/BMPR1A, ALK6/BMPR1B) and type II receptors (BMPR2, ACVR2A, ACVR2B) are engaged.
• Ligand-receptor binding specificity is encoded by a small number of residues, as shown for GDF-5, where a single residue defines binding specificity to BMP receptor IB.
• Extracellular antagonists such as noggin and crossveinless 2 block BMP receptor binding, and a BMP-2 mutant (L51P) that is BMP receptor IA binding-deficient still inhibits noggin [1,7].
• Small-molecule kinase inhibitors such as LDN-212854 bind the BMP receptor kinase ALK2 with high selectivity, providing chemical tools to probe BMP receptor function.
• BMP receptor binding is dysregulated in vascular calcification, pulmonary vascular remodeling, and cancer metastasis, making it a target for functional genomics and therapeutic development [4,5,8].
Description
BMP receptor binding (GO:0070700) is the molecular function of physically interacting with a bone morphogenetic protein (BMP) receptor. It is the initiating event of canonical BMP signaling, in which extracellular ligands such as BMP-2, BMP-4, BMP-9, and GDF-5 engage type I and type II serine/threonine kinase receptors on the cell surface. Because this binding event dictates downstream SMAD phosphorylation and transcriptional output, it is a central node for understanding development, tissue homeostasis, and disease. Researchers study BMP receptor binding to define ligand-receptor specificity, to identify antagonists and inhibitors, and to build quantitative models of signaling flux [1,2,6]. The function is experimentally tractable: tagged receptor libraries allow cell-surface ligand binding to be quantified, and structural studies reveal how individual residues and extracellular modulators control receptor engagement [6,7]. As a result, GO:0070700 is a useful annotation for interpreting genome-wide screens, proteomic interaction maps, and disease-associated variants that converge on BMP receptor complexes.
BMP receptor binding At A Glance
| GO ID | GO:0070700 |
|---|---|
| GO term | BMP receptor binding |
| Ontology | molecular_function |
| Synonym | bone morphogenetic protein receptor binding |
| Major function | Binding to a BMP receptor, initiating BMP/TGF-beta signal transduction |
| Representative ligands | BMP-2, BMP-4, BMP-9, GDF-5 |
| Representative receptors | ALK2/ACVR1, ALK3/BMPR1A, ALK6/BMPR1B, BMPR2, ACVR2A, ACVR2B |
| Modulators | Noggin, crossveinless 2, LDN-212854 |
| Disease relevance | Vascular calcification, pulmonary vascular remodeling, cancer metastasis |
What Is GO:0070700?
In the Gene Ontology, GO:0070700 (BMP receptor binding) is a molecular function term defined as binding to a BMP receptor. Its synonym is bone morphogenetic protein receptor binding. This function describes the selective, non-covalent interaction between a ligand or modulator and a BMP receptor, and it is the molecular prerequisite for receptor activation and downstream signaling.
Why Is BMP receptor binding Important in Cell Biology?
BMP receptor binding is important because it is the gatekeeper of BMP signaling, a pathway that controls cell fate, differentiation, and tissue remodeling. The specificity of this binding event determines which receptor complexes assemble and which SMAD effectors are activated, so even single-residue changes can redirect signaling. Extracellular antagonists and small-molecule inhibitors that interfere with BMP receptor binding provide experimental and therapeutic control over the pathway [1,2]. Dysregulated BMP receptor binding is linked to vascular calcification, pulmonary vascular growth and remodeling, and lung-specific metastasis, underscoring its translational relevance [4,5,8].
• Defines the first step of BMP/TGF-beta signaling and controls downstream SMAD activation.
• Determines ligand-receptor specificity through a small number of critical residues.
• Provides a target for natural antagonists such as noggin and crossveinless 2 [1,7].
• Enables chemical interrogation of BMP receptors with selective inhibitors like LDN-212854.
• Is dysregulated in vascular calcification and atherogenesis driven by cationic eosinophil proteins.
• Contributes to pulmonary vascular growth and remodeling through BMP-9 signaling.
• Is implicated in cancer metastasis via regulation of BMPR1A lysosomal degradation.
• Supports development of tagged receptor libraries for quantitative cell-surface binding assays.
• Offers a mechanistic explanation for disease-associated variants in BMP pathway genes.
• Guides CRISPR functional genomics screens that test causal roles of BMP receptor binding partners [3,8].
Molecular Mechanism of BMP receptor binding
Ligand recognition and receptor engagement
In simple terms: BMP ligands grab onto BMP receptors on the cell surface, like a key fitting a lock.
BMP receptor binding begins when an extracellular BMP ligand contacts the extracellular domain of a type I or type II BMP receptor. Tagged Halo- and SNAP-tagged BMP/TGF-beta receptor libraries allow this cell-surface ligand binding to be quantified and compared across receptor complexes. The interaction is selective: for GDF-5, a single residue defines binding specificity to BMP receptor IB, demonstrating that ligand-receptor pairing is encoded at the atomic level.
Receptor complex assembly and specificity
In simple terms: Different BMP ligands prefer different receptor combinations, which decides which signals turn on.
BMP receptor binding nucleates assembly of type I and type II receptor complexes. The composition of these complexes determines downstream signaling output, and structural analysis of the Chordin family member crossveinless 2 shows how extracellular modulators can block BMP-2 receptor binding and thereby prevent complex formation. Selective chemical probes such as LDN-212854 bind the BMP receptor kinase ALK2 with high selectivity, confirming that individual receptor kinases can be targeted within these complexes.
Antagonism and modulation of binding
In simple terms: Some proteins and drugs can block BMP ligands from reaching their receptors.
BMP receptor binding is negatively regulated by extracellular antagonists. Noggin is a classic BMP antagonist, and the BMP-2 mutant L51P, which is BMP receptor IA binding-deficient, still inhibits noggin, illustrating that binding-deficient ligands can act as modulators of the pathway. Crossveinless 2 blocks BMP-2 receptor binding through its structural architecture, providing a second example of antagonist control. Small molecules such as LDN-212854 add a pharmacological layer of control by occupying the receptor kinase domain.
Binding-deficient ligands and disease-associated modulators
In simple terms: When binding goes wrong, it can contribute to diseases like vascular calcification and metastasis.
Cationic proteins from eosinophils bind BMP receptors and promote vascular calcification and atherogenesis, directly linking BMP receptor binding to vascular pathology. BMP-9 controls pulmonary vascular growth and remodeling, showing that physiological binding by specific ligands shapes vascular beds. In cancer, lysosomal protein transmembrane 5 promotes lung-specific metastasis by regulating BMPR1A lysosomal degradation, which alters the availability of BMP receptors for ligand binding.
Key Genes Involved in GO:0070700 BMP receptor binding
The following genes and proteins are central to BMP receptor binding, either as ligands, receptors, antagonists, or regulatory modulators.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BMP2 | BMP ligand that binds BMP receptors | L51P mutant is BMP receptor IA binding-deficient and inhibits noggin |
| BMP9 (GDF2) | BMP ligand that controls pulmonary vascular growth | BMP-9 controls pulmonary vascular growth and remodeling |
| GDF5 | BMP ligand with receptor specificity | A single residue defines binding specificity to BMP receptor IB |
| ACVR1 (ALK2) | Type I BMP receptor kinase | Selective binding by LDN-212854 |
| BMPR1A (ALK3) | Type I BMP receptor | Lysosomal degradation of BMPR1A promotes lung-specific metastasis |
| BMPR1B (ALK6) | Type I BMP receptor | GDF-5 binding specificity to BMP receptor IB |
| BMPR2 | Type II BMP receptor | Included in Halo- and SNAP-tagged BMP/TGF-beta receptor libraries |
| ACVR2A | Type II BMP receptor | Included in tagged receptor libraries for ligand binding quantification |
| ACVR2B | Type II BMP receptor | Included in tagged receptor libraries for ligand binding quantification |
| NOG (Noggin) | Extracellular BMP antagonist | Inhibited by BMP-2 mutant L51P |
| CV2 (Crossveinless 2) | Chordin family BMP antagonist | Blocks BMP-2 receptor binding |
| LTMB5 | Regulator of BMPR1A lysosomal degradation | Promotes lung-specific metastasis via BMPR1A degradation |
| SMAD1 | Downstream effector of BMP signaling | Readout of BMP receptor binding activation |
| SMAD5 | Downstream effector of BMP signaling | Readout of BMP receptor binding activation |
| SMAD9 | Downstream effector of BMP signaling | Readout of BMP receptor binding activation |
| ENG (Endoglin) | TGF-beta/BMP co-receptor | Modulates BMP receptor complex function |
| BAMBI | Pseudo-receptor that modulates BMP signaling | Modulates BMP receptor binding and signaling |
How Is BMP receptor binding Regulated?
BMP receptor binding is regulated at multiple levels. Extracellular antagonists such as noggin and crossveinless 2 directly block ligand-receptor interaction [1,7]. Receptor availability is controlled by trafficking and degradation; lysosomal protein transmembrane 5 regulates BMPR1A lysosomal degradation and thereby alters the pool of receptors available for binding. Small-molecule inhibitors such as LDN-212854 bind the BMP receptor kinase ALK2 and provide pharmacological regulation of downstream signaling. Tagged receptor libraries enable quantitative assessment of how these regulatory layers change cell-surface ligand binding.
BMP receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BMPR1A | Lung-specific metastasis | Knockout or knockdown in cancer cell lines followed by metastasis assays |
| BMP9 (GDF2) | Pulmonary vascular growth and remodeling | Endothelial cell knockout and pulmonary vascular remodeling models |
| ACVR1 (ALK2) | Vascular calcification and atherogenesis | Point-mutation knock-in of kinase domain variants and calcification assays [2,5] |
| GDF5 | Skeletal and joint development | Point-mutation knock-in at the receptor-specificity residue |
| BMP2 | Bone and vascular biology | Knock-in of the L51P binding-deficient mutant |
Vascular calcification and atherogenesis
Cationic proteins from eosinophils bind BMP receptors and promote vascular calcification and atherogenesis, directly implicating BMP receptor binding in vascular disease. This mechanism links inflammatory cell products to osteogenic signaling in the vessel wall.
Pulmonary vascular remodeling
BMP-9 controls pulmonary vascular growth and remodeling, showing that ligand-specific BMP receptor binding is required for normal pulmonary vascular homeostasis. Disruption of this binding axis may contribute to vascular remodeling diseases.
Cancer metastasis
Lysosomal protein transmembrane 5 promotes lung-specific metastasis by regulating BMPR1A lysosomal degradation, which reduces receptor availability and alters BMP receptor binding-dependent signaling. This connects BMP receptor binding to organ-specific metastatic tropism.
Skeletal and developmental disorders
The BMP-2 mutant L51P is BMP receptor IA binding-deficient yet inhibits noggin, demonstrating that altered BMP receptor binding can change the balance of BMP signaling in bone and development. GDF-5 binding specificity to BMP receptor IB further highlights how receptor binding determines skeletal phenotypes.
From BMP receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene alter BMP receptor binding? | CRISPR knockout cell line followed by tagged ligand binding assay |
| Does a specific residue control receptor specificity? | Point-mutation knock-in of the ligand or receptor |
| Does a disease variant change receptor binding affinity? | Knock-in of the variant and quantitative binding assays |
| Where and when does BMP receptor binding occur? | Tagged knock-in of the receptor with Halo or SNAP tags |
| Does overexpression of a ligand increase signaling? | Overexpression cell model with SMAD phosphorylation readout |
| Which genes are required for BMP receptor binding-dependent phenotypes? | CRISPR library screening with a binding or signaling readout [3,8] |
How to Study the BMP receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Tagged receptor ligand binding assay | Cell-surface binding of BMP ligands to receptors | Quantify BMP receptor binding in live cells |
| Surface plasmon resonance | Binding affinity and kinetics | Compare wild-type and mutant ligand-receptor pairs |
| Crystal structure analysis | Atomic details of receptor-ligand or antagonist complexes | Explain how antagonists block BMP-2 receptor binding |
| Kinase inhibitor binding assay | Selective binding to BMP receptor kinases | Characterize LDN-212854 binding to ALK2 |
| SMAD phosphorylation immunoblot | Downstream pathway activation | Confirm that binding leads to signaling |
| CRISPR knockout screen | Genes required for binding-dependent phenotypes | Identify regulators of BMP receptor binding |
| Vascular calcification assay | Mineralization of vascular cells | Test eosinophil cationic protein effects on BMP receptors |
| Pulmonary vascular remodeling model | Vessel growth and remodeling | Test BMP-9-dependent binding in vivo |
Quantitative cell-surface ligand binding assays
Halo- and SNAP-tagged BMP/TGF-beta receptor libraries enable quantification of cell-surface ligand binding, allowing direct measurement of BMP receptor binding in live cells. These assays can compare wild-type and mutant receptors and test the effect of antagonists or inhibitors [1,2].
Structural and biochemical characterization
Crystal structure analysis of crossveinless 2 bound to BMP-2 reveals how antagonists block BMP receptor binding. Structural studies of GDF-5 define the residue that determines binding specificity to BMP receptor IB. Kinase inhibitor co-crystal structures show selective binding to ALK2.
Functional genomics and CRISPR screening
CRISPR knockout and knock-in models can test whether candidate genes are required for BMP receptor binding and downstream signaling. For example, knockout of BMPR1A regulators can be combined with metastasis assays to link binding to phenotype. Tagged receptor knock-ins support imaging and proteomic readouts.
Disease-relevant phenotypic assays
Vascular calcification assays can test whether cationic proteins that bind BMP receptors promote calcification. Pulmonary vascular growth and remodeling assays can test BMP-9-dependent binding. These phenotypic assays connect molecular binding events to disease biology.
How CRISPR Can Be Used to Study GO:0070700 BMP receptor binding
Knockout
CRISPR knockout of BMP receptors or ligands can abolish BMP receptor binding and reveal its requirement for downstream signaling and disease phenotypes. For example, knockout of BMPR1A regulators can be used to test effects on lung-specific metastasis. Knockout of receptors in tagged libraries can validate binding specificity.
Point Mutation
Point-mutation knock-in can test the role of individual residues in BMP receptor binding. The GDF-5 residue that defines binding specificity to BMP receptor IB is a prime target for such experiments. The BMP-2 L51P mutation, which is BMP receptor IA binding-deficient, can be introduced to study antagonist interactions.
Knock-in
Knock-in of Halo or SNAP tags on BMP receptors enables quantitative cell-surface ligand binding assays in the native genomic context. Knock-in of disease-associated variants can test whether they alter BMP receptor binding affinity or specificity.
Overexpression
Overexpression of BMP ligands or receptors can increase BMP receptor binding and amplify downstream signaling, providing a gain-of-function system to study pathway output. Overexpression of antagonists such as noggin or crossveinless 2 can reduce binding and test inhibitory mechanisms [1,7].
How EDITGENE Supports BMP receptor binding Research
Researchers studying BMP receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand-receptor interaction, receptor complex assembly, or downstream signaling. EDITGENE provides CRISPR-based cell models and screening services that enable precise, reproducible interrogation of GO:0070700 in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for BMP receptor binding research.
Frequently Asked Questions About BMP receptor binding
What is GO:0070700?
GO:0070700 is the Gene Ontology molecular function term BMP receptor binding, defined as binding to a BMP receptor, with the synonym bone morphogenetic protein receptor binding.
What is BMP receptor binding?
BMP receptor binding is the physical interaction between a BMP ligand or modulator and a BMP receptor, initiating BMP/TGF-beta signaling.
What genes are involved in BMP receptor binding?
Key genes include BMP2, BMP9, GDF5, ACVR1, BMPR1A, BMPR1B, BMPR2, ACVR2A, ACVR2B, NOG, and CV2 [1,2,3,4,6,7].
Which receptors bind BMP ligands?
Type I receptors such as ALK2/ACVR1, ALK3/BMPR1A, and ALK6/BMPR1B, and type II receptors such as BMPR2, ACVR2A, and ACVR2B bind BMP ligands [3,6].
How is BMP receptor binding measured?
Tagged Halo- and SNAP-tagged receptor libraries allow quantification of cell-surface ligand binding in live cells.
What blocks BMP receptor binding?
Extracellular antagonists such as noggin and crossveinless 2 block BMP receptor binding, and small molecules like LDN-212854 bind BMP receptor kinases [1,2,7].
What diseases involve BMP receptor binding?
Vascular calcification, atherogenesis, pulmonary vascular remodeling, and cancer metastasis have been linked to BMP receptor binding [4,5,8].
Can CRISPR be used to study BMP receptor binding?
Yes, CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models can test the role of specific genes and residues in BMP receptor binding [1,3,6,8].
What is the role of GDF-5 in BMP receptor binding?
A single residue of GDF-5 defines binding specificity to BMP receptor IB, making it a key model for receptor specificity.
How does BMP-9 control pulmonary vascular growth?
BMP-9 controls pulmonary vascular growth and remodeling, demonstrating ligand-specific BMP receptor binding in the vasculature.
Conclusion
GO:0070700 (BMP receptor binding) is a molecular function that initiates BMP/TGF-beta signaling and determines receptor complex specificity. Its mechanisms are defined by ligand-receptor residue interactions, extracellular antagonists, and small-molecule inhibitors, and its dysregulation is linked to vascular calcification, pulmonary vascular remodeling, and cancer metastasis. CRISPR-based models and quantitative binding assays provide robust tools to dissect this function and its disease relevance.
References
- 1. Khattab HM et al.. 2019. The BMP-2 mutant L51P: a BMP receptor IA binding-deficient inhibitor of noggin.. J Bone Miner Metab 37(2):199-205 PMID: 29667005
- 2. Williams E et al.. 2018. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.. Bone 109:251-258 PMID: 28918311
- 3. Jatzlau J et al.. 2023. A versatile Halo- and SNAP-tagged BMP/TGFβ receptor library for quantification of cell surface ligand binding.. Commun Biol 6(1):34 PMID: 36635368
- 4. Berrebeh N et al.. 2025. Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling.. Proc Natl Acad Sci U S A 122(26):e2410229122 PMID: 40549904
- 5. Meng Z et al.. 2023. Cationic proteins from eosinophils bind bone morphogenetic protein receptors promoting vascular calcification and atherogenesis.. Eur Heart J 44(29):2763-2783 PMID: 37279475
- 6. Nickel J et al.. 2005. A single residue of GDF-5 defines binding specificity to BMP receptor IB.. J Mol Biol 349(5):933-47 PMID: 15890363
- 7. Zhang JL et al.. 2008. Crystal structure analysis reveals how the Chordin family member crossveinless 2 blocks BMP-2 receptor binding.. Dev Cell 14(5):739-50 PMID: 18477456
- 8. Jiang B et al.. 2022. Lysosomal protein transmembrane 5 promotes lung-specific metastasis by regulating BMPR1A lysosomal degradation.. Nat Commun 13(1):4141 PMID: 35842443
